With 48% Ownership, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Has Piqued the Interest of Institutional Investors
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Cuts Target Price to $10
Finding Family DNA Podcast Series Wins Gold!
Ayana Bio to Showcase Plant Cell Advantage Health & Wellness Ingredients at SupplySide West 2024
Ginkgo Bioworks Falls -7.0%
Ginkgo Bioworks Holdings Inc (DNA) Q2 2024 Earnings Call Highlights: Strategic Restructuring ...
Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 48%
Lesaffre Strengthens Its Research, Development & Innovation (RD&I) With the Acquisition of Altar, a Company Owned by Ginkgo Bioworks
Virica Biotech and Ginkgo Bioworks Announce Partnership to Accelerate AAV Gene Therapy Manufacturing
NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
TD Cowen Initiates Ginkgo Bioworks(DNA.US) With Buy Rating, Announces Target Price $10
Ginkgo Bioworks Holdings: A Buy Rating on Strategic AI Advancements and Market Expansion
Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology
Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Ginkgo Bioworks Stock Is Rallying Tuesday: Here's Why
Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology
Ginkgo Bioworks Executive Sells Over $1,900 in Stock
Is Ginkgo Bioworks Holdings, Inc. (DNA) A Good High Risk High Reward Growth Stock To Buy?
Express News | Ginkgo Bioworks Awarded $118M U.S. Government HHS Contract